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Partial Splenic Embolization (PSE) is a non-surgical treatment for hypersplenism. It has been reported only in a limited number of patients
with Cystic Fibrosis (CF). We report a case of a female cystic fibrosis patient who developed hypersplenism at the age of 14 and underwent
PSE. Long term results over a period of 14 years after the procedure are presented.
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This female patient was three years old when CF was
diagnosed. She was found to be homozygous for the
mutationΔF 508. Nodular biliary cirrhosis was first detected
by ultrasound examination at the age of ten and she was
placed on ursodeoxycholic acid when she was 11 years old.
Oesophagoscopy revealed oesophageal varices grade 0–1.
She had one episode of haematemesis at the age of 14 years.
She gradually developed massive splenomegaly with
hypersplenism, thrombocytopenia and leucopenia. The size
of the spleen on USS examination increased from 120 mm at
the age of 11 to 185 mm at the age of 14 years, whereas
portal diameter remained 15 mm. Clotting and liver function
tests were normal and remained stable (INR 1.02, PT 13.5/
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doi:10.1016/j.jcf.2006.10.00138 U/l, albumin 3.6 g/dl). In the beginning of the 2nd decade
of the patient's life the platelet count decreased markedly
from 300 K/μl to 70 K/μl and the white blood cell count
decreased from 7 K/μl to 1.5 K/μl. Hemoglobin remained
stable. At the age of 14, the patient suffered from severe
discomfort and abdominal pain with laboratory evidence of
hypersplenism.
Partial Splenic Embolization was performed at the age of
14 years. In the immediate postoperative period, the patient
developed fever and abdominal pain for approximately
20 days. She also developed pneumonia with pleural
effusion on the 3rd day, and ascites on 9th day after the
procedure. The most severe complication was gastrointesti-
nal bleeding on the 6th, 7th, 8th and 15th day, requiring three
consecutive blood transfusions. She remained in the hospital
for 28 days. On discharge, the leucocyte and platelet counts
were found to be considerably improved and within normal
levels (Figs. 1 and 2).
Over the following years the patient remained in stable
clinical condition requiring few admissions to the hospital,
mainly for respiratory infections. No deterioration of the
haematological profile was observed. At the present time,ed by Elsevier B.V. All rights reserved.
Fig. 1. Gradual increase of platelet count from 70 to 400 K/μl.
Fig. 2. Increase of leucocyte count from 1.5 to 6 K/μl.
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hypersplenism (Hb 14 g/dl, WCC 7.3 K/μl, PLT 195 K/μl)
and no deterioration of liver function (SGOT 38 U/l, SGPT
15 U/l, γGT 42 U/l, albumin 4.24 g/dl).
The most recent abdominal ultrasound examination
revealed that liver size was within the upper normal limits.
The portal diameter was 14 mm. There were no collateral
pathways and the flow in the portal vein was not increased
nor inverted. All these findings support the absence of portal
hypertension. The spleen had a lobular surface with a non-
homogenous signal and a longitudinal diameter of 100 mm.
The CT scan of the spleen revealed asymmetrical devel-
opment of splenic parenchyma with active tissue at the
anterior surface and cystic non-vascularised areas at the
posterior surface of the spleen. These findings are suggestive
of a marginal enlargement of the residual spleen which
probably represents hypertrophy of splenic mass with scar-
ring and contraction of the infarcted areas.
2. Discussion
Splenomegaly and/or hypersplenism (a related haemato-
logical syndrome resulting in peripheral cytopenia) are
frequent manifestations in patients with cirrhosis and portal
hypertension [1,2]. These complications are encountered
more often than previously in patients with CF due to an
increase of life expectancy in this population. Partial Splenic
Embolization has been performed in patients with liver
cirrhosis accompanied by hypersplenism since the first report
of Maddison in 1973 [3] and has gained increasing popularity
as an alternative to splenectomy [4,5]. The latter has been
associated with an increased mortality rate (as high as 14%)
and with an increased long term risk of sepsis [5]. Partial
Splenic Embolization was initially associated with significant
morbidity and mortality and a high complication rate in-
cluding splenic abscess formation, pancreatitis, pneumonia
and sepsis [6,7]. However, subsequent series report substan-
tially decreased complications [4,5,8]. Compared to splenec-
tomy, the incidence of serious complications is acceptably
low, with mortality not exceeding 6% [5,9]. Long term
studies conclude that PSE is a reasonably safe procedure withlong lasting efficacy in controlling hypersplenism in patients
with cirrhosis [8,10,11] but also in reducing the frequency of
variceal bleeding [8]. However, very limited data are found in
the literature regarding patients with Cystic Fibrosis. Shah
et al. [4] presented two patients with CF and cirrhosis who
successfully underwent PSE for leucopenia and thrombocy-
topenia. Brandt et al. [8] concluded that PSE had long lasting
efficacy in controlling hypersplenism in two patients with
biliary cirrhosis as a consequence of cystic fibrosis. The
longest follow-up duration was 7 years in the former study.
The follow-up of the patient in this report has been longer
than 14 years.
It was decided to have PSE performed on our patient in
view of painful splenomegaly, severe discomfort leading to
dyspnoea and severe thrombocytopenia and leucopenia
raising the risk of life threatening haemorrhage and infection,
respectively. The most severe complication in the immediate
post operative period was gastrointestinal bleeding with
anemia (Hb 6 g/dl). Such complication could result from
embolization particles that escaped through the circulation to
parts of the stomach or intestine. So far to our knowledge
there is no other reference for this complication. According
to the literature the post embolization syndrome – associated
fever of 38 °C and/or abdominal pain – is the most frequent
side effect (55–100%) [4,8–10,12] with duration up to
40 days [9]. Our patient also developed fever and abdominal
pain which lasted for 20 days. According to the literature,
median hospital stay is 8–23 days (range 5–54) [5,8,9]
comparable to our patient's hospitalisation. Pneumonia,
[4,8,10] pleural effusion [4,5,8,10,12] and transient ascites
[9,12] have been also described in many cases, as well as
ours. Potentially lethal postoperative complications which
have been reported in the literature including venous
thrombosis and splenic abscess [9,12–15] were not observed
in our patient.
Over the 14-years follow-up the patient remained in stable
clinical condition, with minimum admissions for respiratory
complains. The abdominal discomfort subsided and her
quality of life greatly improved after the procedure. There
was no recurrence of hypersplenism and the size of spleen
did not alter. No significant changes were observed
214 E. Aslanidou et al. / Journal of Cystic Fibrosis 6 (2007) 212–214concerning the liver parameters and function. The above
findings are in accordance with those observed in other long
term studies [10,11]. Moreover, there were no episodes of
bleeding from oesophageal varices and no evidence of portal
hypertension. This is also consistent with previous studies
reporting reduction of portal venous pressure and portal
venous blood flow after PSE [16].
We suggest that PSE can be an effective alternative for the
management of hypersplenism in CF patients with biliary
cirrhosis. The authors support the option that such patients
deserve early therapeutic intervention before hypersplenism
results in potentially irreversible deterioration of their
condition. It is emphasized that the postoperative quality of
life may justify the immediate risks of this procedure.
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